{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:50:10Z","timestamp":1767149410227,"version":"build-2238731810"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vhri.2019.01.009","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T18:45:24Z","timestamp":1557513924000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Healthcare Resource Utilization and the Cost of Care for Mucopolysaccharidosis I Patients in Iran"],"prefix":"10.1016","volume":"18","author":[{"given":"Majid","family":"Davari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azita","family":"Nabizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maliheh","family":"Kadivar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Abdollahi Asl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vhri.2019.01.009_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vhri.2019.01.009_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-3-24","article-title":"The prevalence of and survival in mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK","volume":"3","author":"Moore","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.vhri.2019.01.009_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/qjmed\/hci128","article-title":"Drugs for exceptionally rare diseases: do they deserve special status for funding?","volume":"98","author":"Hughes","year":"2005","journal-title":"QJM"},{"issue":"13","key":"10.1016\/j.vhri.2019.01.009_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/ajmg.a.32320","article-title":"Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?","volume":"146","author":"Vieira","year":"2008","journal-title":"Am J Med Genet Part A"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.009_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10545-012-9555-1","article-title":"Respiratory and sleep disorders in mucopolysaccharidosis","volume":"36","author":"Berger","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.vhri.2019.01.009_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","article-title":"Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management","volume":"34","author":"Braunlin","year":"2011","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11926-013-0389-0","article-title":"Mucopolysaccharidoses","volume":"16","author":"Cimaz","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.vhri.2019.01.009_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1651-2227.1995.tb13640.x","article-title":"The presenting features of mucopolysaccharidosis type IH (Hurler syndrome)","volume":"84","author":"Cleary","year":"1995","journal-title":"Acta Paediatr"},{"issue":"4","key":"10.1016\/j.vhri.2019.01.009_bib10","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jpeds.2009.07.005","article-title":"Guidelines for the management of mucopolysaccharidosis type I","volume":"155","author":"Martins","year":"2009","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.vhri.2019.01.009_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pediatrneurol.2012.08.010","article-title":"Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up","volume":"47","author":"Jurecka","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.vhri.2019.01.009_bib12","series-title":"Food and Drug Administration","year":"2010"},{"issue":"3","key":"10.1016\/j.vhri.2019.01.009_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","article-title":"Current and potential therapeutic strategies for mucopolysaccharidoses","volume":"39","author":"Noh","year":"2014","journal-title":"J Clin Pharm Therapeut"},{"issue":"3","key":"10.1016\/j.vhri.2019.01.009_bib14","first-page":"667","article-title":"Laronidase for treating mucopolysaccharidosis type I","volume":"6","author":"El Dib","year":"2007","journal-title":"Genet Mol Res"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib15","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human \u03b1-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.009_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","article-title":"Efficacy of recombinant human \u03b1-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme\u00ae) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vhri.2019.01.009_bib19","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I","volume":"9","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.vhri.2019.01.009_bib23","doi-asserted-by":"crossref","first-page":"e26864","DOI":"10.1371\/journal.pone.0026864","article-title":"Cost-of-illness analysis of type 2 diabetes mellitus in Iran","volume":"6","author":"Javanbakht","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.transci.2016.01.025","article-title":"Health care resource utilization and cost of care for haemophilia A and B patients in Iran","volume":"54","author":"Gharibnaseri","year":"2016","journal-title":"Transfusion Apheresis Sci"},{"issue":"7","key":"10.1016\/j.vhri.2019.01.009_bib25","first-page":"748","article-title":"The direct medical costs of breast cancer in Iran: analyzing the patient's level data from a cancer specific hospital in Isfahan","volume":"4","author":"Davari","year":"2013","journal-title":"Int J Prevent Med"},{"issue":"19","key":"10.1016\/j.vhri.2019.01.009_bib26","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","article-title":"Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression","volume":"146","author":"Munoz-Rojas","year":"2008","journal-title":"Am J Med Genet Part A"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-017-0583-7","article-title":"Early disease progression of Hurler syndrome","volume":"12","author":"Kiely","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.vhri.2019.01.009_bib28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s10545-006-0457-y","article-title":"Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome","volume":"29","author":"Thomas","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.vhri.2019.01.009_bib29","series-title":"Laronidase Treatment of Mucopolysaccharidosis I","author":"Wraith","year":"2005"},{"issue":"4","key":"10.1016\/j.vhri.2019.01.009_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jme.2010.037150","article-title":"Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I","volume":"37","author":"Boy","year":"2011","journal-title":"J Med Ethics"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.009_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","article-title":"Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe","volume":"17","author":"P\u00e9ntek","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"39","key":"10.1016\/j.vhri.2019.01.009_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"}],"updated-by":[{"DOI":"10.1016\/j.vhri.2020.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000}}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:11:22Z","timestamp":1761941482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109919300494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"alternative-id":["S2212109919300494"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2019.01.009","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare Resource Utilization and the Cost of Care for Mucopolysaccharidosis I Patients in Iran","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2019.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}